SPCs & Regulatory Exclusivities
We advise on the exclusivities available beyond standard patent protection for products that improve the health of humans, animals and plants
Our Life Sciences Group has deep expertise in Supplementary Protection Certificates (SPCs) and associated pharmaceutical regulatory law. We regularly devise and implement pan-European SPC filing strategies, taking advantage of our wide experience of different practices around Europe. We have been instrumental in developing SPC case law through our advocacy at Europe’s highest court, the CJEU.
Our expertise in the interplay between SPC protection and regulatory exclusivities allows us to consider the wider implications of the choices and investments that our clients wish to make. Our experiences in this area inform our regular due diligence work and our litigation strategies, meaning that we are involved with many of the current and future generations of blockbuster products.
SPCs & Regulatory partners
Meet the SPCs & Regulatory team
Neurim at the CJEU
When the Court of Justice of the European Union acknowledged Neurim’s right to an SPC, it overturned its own jurisprudence in a wide-ranging decision with important implications for SPC policy throughout Europe. One commentator referred to it as “the most important SPC judgment ever.”
Carpmaels & Ransford represented Neurim at the hearing before the UK IPO, and directly instructed counsel in the appeal to the UK High Court and beyond to the Court of Appeal.